News | Breast Imaging | April 01, 2021

National Study Examines US Mammography Screening Rates During Epidemic

Despite a strong rebound in mammography volume, missed mammograms remain an issue

In looking at the broader impact of the COVID-19 pandemic on health and wellbeing, public health experts are examining screening rates for cancer. A new study looking at U.S. mammography screening rates during the first five months of the pandemic found both a strong rebound in breast cancer screening rates and a concerning cumulative deficit in mammograms due to missed appointments, as well as uncovering disparities when looking at screening according to race

Getty Images

April 1, 2021 — In looking at the broader impact of the COVID-19 pandemic on health and wellbeing, public health experts are examining screening rates for cancer. A new study looking at U.S. mammography screening rates during the first five months of the pandemic found both a strong rebound in breast cancer screening rates and a concerning cumulative deficit in mammograms due to missed appointments, as well as uncovering disparities when looking at screening according to race.

The study was released this week in the Journal of the National Cancer Institute.

Conducted by investigators from the Breast Cancer Surveillance Coalition (BCSC), a federally-funded, national network of breast imaging registries, the study sought to quantify the impact of the COVID-19 pandemic on both breast cancer screening and diagnostic mammography services in the U.S. Results suggest that, despite huge declines in the early months of the pandemic, mammography volumes rebounded strongly in summer 2020, as healthcare facilities adapted new protocols to ensure staff and patient safety.

In April 2020, screening mammography utilization was only 1% of expected volume based on comparative historical data. However, by July 2020, rates had rebounded to approximately 90% of pre-pandemic volume. Similar results were observed for diagnostic breast imaging, as opposed to screening imaging, with volumes rebounding to 100% by July 2020. However, researchers note that a substantial cumulative deficit in mammography screening remains, due to missed exam appointments from March through May 2020, and in an effort to reduce that deficit, screening rates will need to be above pre-pandemic levels.

The researchers found that trends in mammography screening were similar by age and risk factors, but identified disparities by race, with the rebound in mammography volume being lower among Hispanic and Asian women.

Reductions in screening and diagnostic imaging rates could lead to delays in diagnosis that cause increased morbidity and mortality due to breast cancer. The BCSC emphasizes that increased attention is needed to better understand specific barriers to healthcare utilization during the pandemic and to develop interventions to overcome these barriers.

Lead author and UVM Cancer Center researcher Brian Sprague, Ph.D., associate professor of surgery at the University of Vermont Larner College of Medicine, notes that further BCSC research is ongoing to understand the impact of reduced mammography utilization during the pandemic on breast cancer detection and outcomes. "This national snapshot is important to help us focus research, outreach and intervention to close gaps that were perhaps created or made worse by the pandemic," said Sprague.

For more information: www.uvm.edu

Related Breast Imaging Videos 

VIDEO: Explaining Dense Breasts

VIDEO: The Impact of COVID-19 on Breast Imaging

VIDEO: Use of Breast MRI Screening in Women With Dense Breasts

Related Content

CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 15, 2021 | By Dave Fornell
April 15, 2021 — The U.S.
#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
While the COVID-19 crisis is challenging, the pandemic is also giving researchers an opportunity to discover new approaches to saving lives. A study published in the JAMA Network Open on Thursday, March 25, 2021, recommends a new way for triaging mammogram patients during times of limited capacity, such as pandemic surges, when individuals may also experience anxiety about COVID-19.

Getty Images

News | Breast Imaging | April 01, 2021
April 1, 2021 — While the COVID-19 crisis is challenging, the pandemic is also giving researchers an opportunity to d